Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

SAN DIEGO, Oct.  03, 2019  (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present three posters at the Infectious Diseases Society of America (IDSA) IDWeek 2019, which takes place October 2-6, 2019, in Washington, D.C., and four posters, including a late-breaking poster, at the 9th Trends in Medical Mycology (TIMM), which takes place October 11-14, 2019, in Nice, France.

Cidara Therapeutics to Present New Clinical and Preclinical Data at Two Upcoming Medical Conferences

Earlier this week, Cidara Therapeutics Inc. (NASDAQ: CDTX) announced a huge deal that catapulted the stock up nearly 50%.

Why This Analyst Sees Cidara Nearly Doubling

Cidara Therapeutics Inc (NASDAQ: CDTX) announced a development and commercialization deal Tuesday for its lead antifungal investigational drug, rezafungin.

Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Cidara Therapeutics Inc (NASDAQ: CDTX) shares were advancing by more than 50% Tuesday after the thinly traded, micro-cap biotech announced a development and commercialization deal for its lead medication rezafungin.

Cidara Rallies On Development Deal For Lead Antifungal Medication

Shares of Cidara Therapeutics Inc. CDTX, +0.00% rocketed 67% in active premarket trading Tuesday, after the biotechnology company announced a partnership with Mundipharma with a total potential value of $568 million to Cidara.

Cidara Therapeutics's stock rockets after commercialization deal with a potential value of up to $568 million

News for Cidara Therapeutics Stock (CDTX)